Like many companies, the effects of the COVID-19 pandemic were clearly felt by Schott in parts of the portfolio. However, its pharmaceutical business did very well, driving overall growth in 2020. “We stayed on course even in these difficult economic times. Therefore, we are quite satisfied with the past fiscal year,” said Dr. Frank Heinricht, chairman of the Board of Management. “This is largely thanks to the groundwork we have done in recent years. We have invested consistently, introduced ma...